Orgalutran (Ganirelix PFS) 0.25mg/0.5ml

ORGALUTRAN (Ganirelix 0.25mg/0.5ml) is a prescription injectable used in fertility treatments to prevent premature ovulation. This pre-filled syringe formulation offers precise dosing convenience. Ganirelix acetate is a GnRH antagonist commonly prescribed during assisted reproductive technology (ART) cycles.

Strength

0.25mg/0.5ml

Pack Size

Storage

Ambient

Manufacturer / TM Owner

ORGANON GMBH

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ganirelix is used to prevent premature ovulation in women undergoing controlled ovarian stimulation for fertility treatments like IVF. It works by blocking natural hormone signals that trigger early egg release, allowing for better synchronization of egg maturation. This medication is typically started during the mid-to-late follicular phase of the menstrual cycle as part of a larger fertility protocol.

Side Effects

Ganirelix helps regulate the timing of ovulation by temporarily suppressing certain hormones. Patients may notice localized effects at the injection site, such as mild redness or discomfort. Some individuals report temporary headaches or mild abdominal bloating during treatment.

Precautions & Warnings

Store Ganirelix at room temperature away from direct light and moisture. Keep out of reach of children and pets. Do not use if the solution is discolored or contains particles. Always follow your healthcare provider’s instructions for proper handling and disposal of used syringes.

Avoid Interactions

Ganirelix may interact with other hormonal medications, including fertility drugs and thyroid treatments. Alcohol and certain supplements may affect how Ganirelix works; consult your doctor before combining substances. Always inform your healthcare provider about all medications and supplements you are taking.

Frequently Asked Questions

Ganirelix is used to prevent premature ovulation during fertility treatments like IVF.

It is given as a subcutaneous injection, typically starting around day 5-6 of the menstrual cycle.

Common side effects may include injection site reactions, headaches, or mild abdominal discomfort.

Ganirelix is not used during pregnancy as it is intended for fertility protocols before conception.

Ganirelix requires a prescription and should be purchased from licensed pharmacies or clinics.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.